CHIEF EXECUTIVE OFFICER
Sat, Feb 15, 2025
Feb 15
exercised or converted securities in DAWN
11,687 shares @ $0.00
Decreased holdings by -8.30%
Net across this filing: +18.10% (+19,638 shares)
Option Exercise
Sale tied to a same-time option exercise
Win rate excludes trades classified as routine (tax, 10b5-1, exercise, gift).
DAWNDay One Biopharmaceuticals, Inc.
HealthcareBiotechnology